Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cyclerion Therapeutics (CYCN) Consolidated Net Income (2019 - 2025)

Historic Consolidated Net Income for Cyclerion Therapeutics (CYCN) over the last 7 years, with Q3 2025 value amounting to -$1.0 million.

  • Cyclerion Therapeutics' Consolidated Net Income changed N/A to -$1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.1 million, marking a year-over-year decrease of 3774.15%. This contributed to the annual value of $7.3 million for FY2023, which is 12837.57% up from last year.
  • Latest data reveals that Cyclerion Therapeutics reported Consolidated Net Income of -$1.0 million as of Q3 2025.
  • In the past 5 years, Cyclerion Therapeutics' Consolidated Net Income registered a high of $13.5 million during Q3 2023, and its lowest value of -$16.2 million during Q2 2021.
  • For the 5-year period, Cyclerion Therapeutics' Consolidated Net Income averaged around -$6.0 million, with its median value being -$5.2 million (2022).
  • Per our database at Business Quant, Cyclerion Therapeutics' Consolidated Net Income surged by 32128.43% in 2023 and then plummeted by 2080.92% in 2025.
  • Cyclerion Therapeutics' Consolidated Net Income (Quarter) stood at -$14.3 million in 2021, then surged by 79.82% to -$2.9 million in 2022, then skyrocketed by 565.74% to $13.5 million in 2023, then plummeted by 110.27% to -$1.4 million in 2024, then rose by 27.31% to -$1.0 million in 2025.
  • Its last three reported values are -$1.0 million in Q3 2025, -$1.7 million for Q2 2025, and -$1.5 million during Q1 2025.